Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT-Trial: Eptinezumab for Painful Diabetic Neuropathy
2022-500338-27-00Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Eptinezumab (Vyepti) with Placebo (saline) (2 arms). Primary endpoint: Change in average pain intensity (NRS 0–10). Started Sep 2023; status: completed.
02
Drugs
eptinezumab
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2022-500338-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500338-27-00.